Intranasal therapies for neonatal hypoxic-ischemic encephalopathy.

Area of Science:

• Neuroscience
• Neonatal Medicine
• Pharmacology

Background:

• Neonatal hypoxic-ischemic encephalopathy (HIE) is a major cause of brain injury in newborns, particularly in low-resource settings.
• Therapeutic hypothermia, standard in high-resource areas, is ineffective and increases mortality in low-resource settings for HIE.
• Intranasal administration presents a low-resource, direct brain delivery method for HIE treatments.

Purpose of the Study:

• To review preclinical literature on intranasal therapies for neonatal HIE.
• To develop a semi-quantitative index to rank intranasal therapies for HIE based on plausibility, efficacy, and accessibility.
• To identify promising intranasal treatments for HIE suitable for diverse resource settings.

Main Methods:

• Searched PubMed and Google Scholar for peer-reviewed articles on intranasal therapies for HIE.
• Used mesh phrases "Neonatal hypoxic-ischemic encephalopathy intranasal" and "Neonatal brain intranasal."
• Included 62 studies describing 34 unique intranasal therapies, analyzing preclinical and limited clinical data.

Main Results:

• Intranasal therapies for HIE have been extensively studied in small animals, less in large animals, and recently in human trials.
• Cell-based therapies ranked highest for potential efficacy in animal models of HIE.
• Current cell-based treatments face accessibility limitations in low-resource settings due to pharmaceutical support requirements.

Conclusions:

• Intranasal therapies demonstrate feasibility and neuroprotective potential for treating neonatal HIE safely and effectively.
• Further research is crucial for translating these findings into human clinical practice.
• Future studies should focus on advanced animal models, pharmaceutics, cell therapies, and neurobehavioral outcomes.